Rani Therapeutics Reports First Quarter 2025 Financial Results; Provides Corporate Update

Core Insights - Rani Therapeutics announced promising preclinical data for RT-114, a bispecific GLP-1/GLP-2 receptor agonist, demonstrating bioequivalence to subcutaneous administration when delivered orally via the RaniPill® capsule [1][7] - The company plans to initiate a Phase 1 clinical trial for RT-114 targeting obesity in mid-2025 [4] - Financial results for Q1 2025 show a net loss of $12.7 million, an improvement from a net loss of $14.8 million in Q1 2024 [5][13] Preclinical Developments - Preclinical studies indicated that RT-114 achieved a relative bioavailability of 111% compared to subcutaneously administered PG-102, with similar pharmacokinetic profiles [7] - Successful oral delivery of semaglutide via the RaniPill® capsule was also reported, showing comparable bioavailability and weight loss to subcutaneous administration [7] Financial Performance - As of March 31, 2025, cash, cash equivalents, and marketable securities totaled $15.9 million, down from $27.6 million at the end of 2024 [7] - Contract revenue for Q1 2025 was $0.2 million, a new revenue stream compared to no contract revenue in Q1 2024 [7] - Research and development expenses decreased to $6.6 million from $7.6 million in the same period last year, primarily due to lower compensation costs [7] Company Overview - Rani Therapeutics is focused on the oral delivery of biologics and drugs, utilizing the RaniPill® capsule technology to replace traditional subcutaneous injections [8] - The company aims to make oral biologics a reality for patients, particularly those living with obesity [2]